In CRC, Marimastat targets MMP-1, MMP-3, MMP-7, and MMP-9, reducing carcinoembryonic antigen levels in CRC; however, despite its good oral bioavailability and favorable phase III trials, it failed to improve overall survival or halt tumor progression, though combination therapies may enhance its efficacy [380]. This evidence concerns the gene MMP9 and neoplasm.